Advertisement
Anesthesiology and Pulmonary Medicine
Subscribe to Anesthesiology and Pulmonary Medicine
View Sample

FREE Email Newsletter

Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results

June 1, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin...

Acurest's Custom CPAP Mask Now Available for Sleep Apnea Sufferers in the U.S.

May 31, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

DALLAS, May 31, 2011 /- Acurest, the world's only provider of custom-made Continuous Positive Airway Pressure (CPAP) nasal masks for the treatment of sleep apnea disorder, announced that the solution is now available to sleep apnea sufferers in the U.S. Made specifically for each...

Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer

May 31, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

MALVERN, Pa., May 31, 2011 /- Fujirebio Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ EIA assay to monitor disease progression during the course of disease and treatment of lung cancer patients....

Advertisement

Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis

May 26, 2011 10:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 26, 2011 /- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of...

Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference

May 26, 2011 5:31 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., May 26, 2011 /- Masimo (NASDAQ: MASI ) today announced that its management is scheduled to present at the Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in Rancho Palos Verdes, California, on Thursday, June 9, 2011, at 8:40 a.m. Pacific Time.  A...

Nix the Knife

May 26, 2011 5:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 26, 2011 /- Patients looking for a quick nip/tuck but don't want to go under the knife now have a way to snap sagging skin into place and outsmart stubborn body fat.  This month, The Body Contouring Center at the renowned JUVA Skin & Laser Center in New York has...

Mylan Launches Generic Version of Roxicodone® Tablets

May 25, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, May 25, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone Hydrochloride (HCI) Tablets USP, 5 mg, 15 mg and 30 mg, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the...

U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care

May 24, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., May 24, 2011 /PRNewswire-USNewswire/ -- Despite significant technological improvements, children reliant on long-term mechanical ventilation often require extensive additional care, including costly hospital stays and emergency visits. A new study led by University of...

Advertisement

$10 Million Verdict Against Johnson & Johnson Unit for Toxic Motrin Reaction, Announces The Jensen Law Firm

May 24, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, May 24, 2011 /- Members of Fort Worth, Texas-based Jensen Law Firm ( www.stevensjohnsonsyndrome.org ) are pleased to announce a $10 million verdict in compensatory damages against Johnson & Johnson's McNeil Consumer Products (NYSE: JNJ ) unit on behalf of 13-year-old...

ResMed Announces New iPhone App

May 24, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 24, 2011 /- ResMed (NYSE: RMD ) today released the ResMed Sleep Assessment app, a novel new app for iPhone that lets users record themselves during sleep. The app also includes a clinically validated questionnaire that assesses their risk and other helpful features to...

Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment

May 24, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR ), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella...

Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

May 24, 2011 2:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 24, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis...

Pacira Pharmaceuticals, Inc. Announces EXPARELâ„¢ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting

May 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., May 23, 2011 /- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the...

Advertisement

Mylan Launches Generic Version of Depakote® Sprinkle Capsules

May 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, May 23, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Divalproex Sodium Capsules USP, 125 mg, the generic version of Abbott's Depakote® Sprinkle Capsules, a treatment for certain types of seizures.  ...

A Nightshirt to Monitor Sleep

May 22, 2011 8:33 pm | by Massachusetts Institute of Technology | News | Comments

A newly developed smart shirt detects the wearer's stage of sleep via respiration patterns.

Infinity Pharma: One cancer drug advances, one ends development

May 19, 2011 10:42 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Infinity Pharmaceuticals Inc. is launching a Phase 2 trial of its potential treatment for non-small cell lung cancer, retaspimycin HCl in combination with the approved chemotherapy drug, Taxotere, marketed by French drug maker Sanofi.

Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA

May 19, 2011 5:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, May 19, 2011 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy announced today that Repligen Corporation has received approval from the U.S. Food and Drug Administration to commence a Phase I safety study in healthy volunteers for RG3039, formerly called...

Takeda to Acquire Nycomed

May 18, 2011 11:37 pm | by Bio-Medicine.Org | News | Comments

OSAKA, Japan, and ZURICH, May 19, 2011 /- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for...

Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD

May 18, 2011 9:41 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., May 18, 2011 /- Pearl Therapeutics Inc. presented detailed efficacy and safety results today from the Company's phase 2b study of PT003  (GFF MDI) in patients with moderate-to-very severe COPD during a late-breaker poster session at the annual meeting of the...

ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society

May 18, 2011 9:41 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., May 18, 2011 /- AcelRx Pharmaceuticals, Inc. announced today that the results from its Phase 2 clinical studies related to two product candidates, ARX-01 Sufentanil NanoTab(R) PCA System, which is designed to solve the problems associated with post-operative...

Maine Medical Equipment Providers Back Congressional Bill to Repeal Flawed Medicare Bidding Program

May 16, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

PORTLAND, Maine, May 16, 2011 /PRNewswire-USNewswire/ -- Maine home medical equipment and services (HME) providers support H.R. 1041, a bipartisan bill in Congress to repeal the controversial Medicare "competitive" bidding program for home medical equipment and services.   "If...

Massachusetts Home Medical Equipment Providers Back Federal Legislation to Repeal Controversial Medicare Bidding Program

May 16, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

BOSTON, May 16, 2011 /PRNewswire-USNewswire/ -- Massachusetts providers of home medical equipment and services (HME) support H.R. 1041, a bipartisan bill in Congress to repeal the flawed, controversial Medicare "competitive" bidding program for medically required equipment and services....

Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO

May 16, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, May 16, 2011 /- Eli Lilly and Company (NYSE: LLY ) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7, 2011, including results from PARAMOUNT, a Phase III study of...

MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference

May 13, 2011 6:39 am | by Bio-Medicine.Org | News | Comments

GAITHERSBURG, Md., May 13, 2011 /- MedImmune announced today it will present eight abstracts at the American Thoracic Society (ATS) International Conference in Denver, CO, May 13-18, 2011.  "These data advance our understanding of thoracic diseases, highlighting our continued...

Mylan Launches Generic Version of Risperdal® M-Tab®

May 13, 2011 4:47 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, May 13, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets (ODT), 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal® M-Tab®, a...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading